International network for natural sciences – research journal
  • mendeley icon
  • linkedin icon
  • google plus icon
  • twitter icon
  • google scholar icon
  • facebook icon

Diagnosis and management of diabetic nephropathy using novel biomarkers, CXCL16 and TNF-α receptors 1and 2

By: Fahmy Tawfik Ali, Eman M. Abd El Azeem, Samia Abdelsalam Hassan, Hala Fawzy Hekal

Key Words: Diabetic nephropathy, eGFR, CXCL16, TNFR1, TNFR2

Int. J. Biosci. 15(4), 515-523, October 2019.

DOI: http://dx.doi.org/10.12692/ijb/15.4.515-523

Certification: ijb 2019 0351 [Generate Certificate]

Abstract

CXCL16 is expressed at a low level in epithelial cells in the normal kidney and play a crucial role in regulating inflammation and tissue injury. The function of TNFα is mediated by two structurally distinct receptors, TNFR1 and TNFR2. The reliability of current tests in predicting the onset, progression and response to various regimens for diabetic nephropathy is still under debate; and it has engendered a search for more sensitive and specific biomarkers. This study was aimed to evaluate the role of some relevant biomarkers in the pathogenesis of DN and that potentially may be used to predict the onset and/or monitor the progression of nephropathy. A total of Seventy Egyptian subjects, including 28 patients with diabetic nephropathy (DN group), 20 type 2 diabetes mellitus patients (T2DM group), and 22 healthy controls of similar age and gender (control group), were enrolled in this study. Serum levels of CXCL16 and TNFR1 & TNFR2 were measured using ELISA technique. Diabetic and renal biomarkers were measured in all subjects. The results showed drastic elevation in the levels of CXCL16, TNFR1, TNFR2, kidney function tests (except eGFR was highly significant decreased) and lipid profile parameters in diabetic nephropathy patients when compared to the control group. CXCL16, TNFR1 and TNFR2 showed high accuracy in the nephropathy group. TNFRs 1 & 2 and CXCl16 may be early, highly sensitive and specific markers and they could be used as a useful promising biomarker for early detection of diabetic nephropathy.

| Views 14 |

| Views 14 |

Diagnosis and management of diabetic nephropathy using novel biomarkers, CXCL16 and TNF-α receptors 1and 2

Al-Lamki RS, Mayadas TN. 2014. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney International 87(2), 281-296.

Boonloh K, Lee ES, Kim HM, Kwon MH, Kim YM, Pannangpetch P, Kongyingyoes B, Kukongviriyapan U, Thawornchinsombut S, Lee EY, Kukongviriyapan V, Chung CH. 2018. Rice bran protein hydrolysates attenuate diabetic nephropathy.

Butler AR. 1975. The Jaffe reaction. Identification of the coloured species. Clin. Chem. Acta 227, 232.

Chan FKM, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354.

Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. NATURE REVIEWS | Immunology 11, 98-107.

Elewa U, Sanchez-Niño MD, Martin-Cleary IMC, Sanz AB, Perez-Gomez MV, Fernandez-Fernandez B, Ortiza A. 2016. Circulating CXCL16 in Diabetic Kidney Disease. Kidney Blood Press Res; 41, 663-671.

Fernández-Juárez G, Perez JV, Fernández JLL, Martinez-Martinez E, Cachofeiro V, Lucia VB, Ribera AMT, Abreu AM, Cordon A, Dominguez JAO, Terente MP. 2017. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy. Nephrology 22(5), 354-360.

Fernández-Real JM, Vendrell J, Garcı´a I, Ricart W, Valle`s M. 2012. Structural damage in diabetic nephropathy is associated with TNF- system activity. Acta Diabetol 49, 301-305.

Fineberg D, Jandeleit-Dahm KAM, Cooper ME. 2013. Diabetic nephropathy: diagnosis and treatment. Nat. Rev. Endocrinol 9, 713-723.

Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.

Gohda T, Maruyama S, Kamei N, Yamaguchi S, Shibata T, Murakoshi M, Horikoshi S, Tomino Y, Ohsawa I, Gotoh H, Nojiri S, Suzuki Y. 2017. Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis. Scientific Reports 7, 43520.

Gohda T, Niewczas MA, Ficociello LH. 2012. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23, 516-524.

Gutwein P, Abdel-Bakky MS, Doberstein K, Schramme A, Beckmann J, Schaefer L, Amann K, Doller A, Kämpfer-Kolb N, Abdel-Aziz AA, El Sayed ESM, Pfeilschifter J. 2009. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J. Cell. Mol. Med 13(9B), 3809-3825.

Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K. 1991. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40 (6), 1007-12.

Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Nino MD, Benito-Martin A, Ruiz-Ortega M, Egido J, Ortiz A. 2012. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 81, 1098-1107.

Izumi Y, Yabe D, Taniguchi A, Fukushima M, Nakai Y, Hosokawa M. 2013. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 99(2), 145-50.

Kaplan A. 1984. Quantitative determination of blood urea. Clin. Chem 1257, 1260.

Kurashina T, Nagasaka S, Watanabe N, Yabe D, Sugi N, Nin K. 2014. Circulating TNF receptor 2 is closely associated with the kidney function in non-diabetic Japanese subjects. J Atheroscler Thromb 21(7), 730-8.

Liang H, Ma Z, Peng H, He L, Hu Z, Wang Y. 2016. CXCL16 Deficiency Attenuates Renal Injury and Fibrosis in Salt-Sensitive Hypertension. Scientific Reports 6, article number 28715.

Ma Z, Jin X, He L, Wang Y. 2016. CXCL16 regulates renal injury and fibrosis in experimental renal artery Stenosis. Am J Physiol Heart Circ Physiol 311, H815-H821.

Matloubian M, David A, Engel S, Ryan J, Cyster J. 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 1(4), 298-304.

Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. 2017. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Scientific Reports 7, 45477. DOI: 10.1038/srep 45477.

Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS. 2012. Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. Am Soc Nephrol 23, 507-515.

Norlander AE, Saleh MA, Madhur MS. 2013. CXCL16 A Chemokine-Causing Chronic Kidney Disease. Hypertension 62, 1008-1010.

Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, Knowler WC, Niewczas MA, Krolewski AS. 2016. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int 89(1), 226-234.

Santee SM, Owen-Schaub LB. 1996. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J. Biol. Chem 271, 21151-21159.

Sharma A, Kiran P, Ajai B. 2013. Spot urine protein/creatinine ratio-A quick and accurate method for diagnosis of pre-eclampsia. Open Journal of Obstetrics and Gynecology 3, 609-612.

Speeckaert MM, Speeckaert R, Laute M, Vanholder R, Delanghe JR. 2012. Tumor Necrosis Factor Receptors: Biology and Therapeutic Potential in Kidney Diseases. Am J Nephrol 36, 261-270.

Trinder P. 1969. Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor. Ann. Clin. Biochem 6, 24-25.

Trivelli LA. 1971. Quantitative determination of whole blood glycohemoglobin A1c. New Engl. J. Med 284:353.

Vielhauer V, Mayadas TN. 2007. Functions of TNF and its Receptors in Renal Disease: Distinct Roles in Inflammatory Tissue Injury and Immune Regulation. Seminars in Nephrology 27(3), pp 286-308.

Wang C, Li Q, Zhen J, Xu Y, Sun S. 2015. Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy. Int J Clin Exp Pathol 8(12), 15696-15707.

Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K. 1986. Urinary protein as measured with pyrogallol red-molybdate complex manually and in Hitachi 726 automated analyser. Clin Chem 32, 1551-1544.

Woodhouse S, Batten W, Hendrick H, Malek PA. 2006. The Glomerular Filtration Rate: An Important Test for Diagnosis, Staging, and Treatment of Chronic Kidney Disease. LABMEDICINE 37(4), 244-246.

Young D, Pestaner L. 1975. Determination of serum triacylglycerols. Clin. Chem 21, 5.

Zhao L, Wu F, Jin L, Lu T, Yang L, Pan X, Shao C, Li X, Lin Z. 2014. Serum CXCL16 as a Novel Marker of Renal Injury in Type 2 Diabetes Mellitus. PLOS ONE 9(1), 1-7.

Fahmy Tawfik Ali, Eman M. Abd El Azeem, Samia Abdelsalam Hassan, Hala Fawzy Hekal.
Diagnosis and management of diabetic nephropathy using novel biomarkers, CXCL16 and TNF-α receptors 1and 2.
Int. J. Biosci. 15(4), 515-523, October 2019.
https://innspub.net/ijb/diagnosis-management-diabetic-nephropathy-using-novel-biomarkers-cxcl16-tnf-%ce%b1-receptors-1and-2/
Copyright © 2019
By Authors and International Network for
Natural Sciences (INNSPUB)
https://innspub.net
brand
innspub logo
english language editing
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Publish Your Article
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Submit Your Article
INNSPUB on FB
Email Update